Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06922318 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The COSMYC Trial (COmbined Suppression of MYC)

StatusRecruiting
PhasePhase 2
Started2025-08-19
View on ClinicalTrials.gov ↗

Amendment history

2026-06-16
Study Status, Arms and Interventions v4
Re-verified, no change to tracked fields
2025-09-11
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v3
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-09→confirmed 2025-08-19
Study sitesdetails revised at 1 of 1 site
2025-09-02
Study Status v2
Start date2025-08-30→2025-09
2025-06-17
Study Identification, Study Status v1
Primary completion date2031-06-30→2031-08-30
Completion date2031-06-30→2031-08-30
Start date2025-06-30→2025-08-30
2025-04-03
Original filing
This research is being done to determine if receiving the combination of testosterone and ZEN-3694 followed by the combination of enzalutamide plus ZEN-3694 will decrease the size of tumors in patients with prostate cancer that has become resistant to castration and other therapies. The investigators also want to determine if dosing first with the combination of testosterone and ZEN-3694 may cause enzalutamide and ZEN-3694 to work more effectively.
Trial Details
NCT Number NCT06922318
Lead Sponsor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators: Zenith Epigenetics, National Cancer Institute (NCI)
Conditions Metastatic Castration-resistant Prostate Cancer
Enrollment 50 participants
Start Date 2025-08-19
Primary Completion 2031-08-30 (estimated)
Study Completion 2031-08-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-18